Table 1.
Day 100 efficacy results from phase 2/3 randomized double-blind trials of maribavir versus placebo in allogeneic HCT recipients*
*
Intention-to-treat population (data are from Marty et al 20113 and Winston et al 200823 ).
†3:1 randomization with a combined placebo group for all dose levels; only seropositive recipients.
‡2:1 randomization; seropositive recipients and seronegative recipients with a seropositive donor (D+/R−) were eligible.
